Neumora Therapeutics reports Q3 EPS miss, lead product in Phase 3 trials for major depressive disorder.

Neumora Therapeutics, a clinical-stage biopharmaceutical firm, reported a Q3 EPS of ($0.37) vs estimates. Nine brokers have given the company a "Moderate Buy" average recommendation, with a consensus target price of $22.33. The firm's lead product, navacaprant (NMRA-140), is in Phase 3 trials for major depressive disorder. Institutional investors and hedge funds have been adding to their stakes in the company, with 47.65% ownership.

August 10, 2024
3 Articles